Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors

被引：0
|
作者：
Teixeira, L.
Hickish, T.
Tournigand, C.
Bachet, J.
Bonetti, A.
Rivera, F.
Boni, C.
Tabernero, J.
Andre, T.
De Gramont, A.
机构：
[1] Hop St Antoine, F-75571 Paris, France
[2] Dorset Canc Network, Bournemouth, Dorset, England
[3] Bournemouth Univ, Bournemouth, Dorset, England
[4] Grp Hosp Pitie Salpetriere, F-75634 Paris, France
[5] Dept Med Oncol, Legnago, Italy
[6] Hosp Univ Marques de Valdecilla, Santander, Spain
[7] Arcispedale S Maria Nuova, Reggio Emilia, Italy
[8] Vall dHebron Univ Hosp, Barcelona, Spain
[9] Hop La Pitie Salpetriere, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3524
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Identification of patients with high-risk stage II colon cancer for adjuvant therapy
    Quah, Hak-Mien
    Chou, Joanne F.
    Gonen, Mithat
    Shia, Jinru
    Schrag, Deborah
    Landmann, Ron G.
    Guillem, Jose G.
    Paty, Philip B.
    Temple, Larissa K.
    Wong, W. Douglas
    Weiser, Martin R.
    DISEASES OF THE COLON & RECTUM, 2008, 51 (05) : 503 - 507
  • [32] Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial (vol 27, pg 2074, 2016)
    Lonardi, S.
    Sobrero, A.
    Rosati, G.
    Di Bartolomeo, M.
    Ronzoni, M.
    Aprile, G.
    Massida, B.
    Scartozzi, M.
    Banzi, M.
    Zampino, M. G.
    Pasini, F.
    Marchetti, P.
    Cantore, M.
    Zaniboni, A.
    Rimassa, L.
    Ciuffreda, L.
    Ferrari, D.
    Barni, S.
    Zagonel, V.
    Maiello, E.
    Rulli, E.
    Labianca, R.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3110 - 3110
  • [33] Multivariate analysis of determinant factors in adjuvant chemotherapy (AC) utilization in patients with stage II colon cancer (CC): Analysis of the National Cancer Database (NCDB).
    Huynh, Donny V.
    Mukkamalla, Shiva Kumar Reddy
    Somasundar, Ponnandai Sadasivan
    Rathore, Ritesh
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [34] Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer
    Cakar, B.
    Varol, U.
    Junushova, B.
    Muslu, U.
    Oner, P. Gursoy
    Surmeli, Z. Gokhan
    Cirak, Y.
    Karaca, B.
    Sezgin, C.
    Karabulut, B.
    Uslu, R.
    JOURNAL OF BUON, 2013, 18 (02): : 372 - 376
  • [35] The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
    Andre, Thierry
    Iveson, Timothy
    Labianca, Roberto
    Meyerhardt, Jeffrey A.
    Souglakos, Ioannis
    Yoshino, Takayuki
    Paul, James
    Sobrero, Alberto
    Taieb, Julien
    Shields, Anthony F.
    Ohtsu, Atsushi
    Grothey, Axel
    Sargent, Daniel J.
    CURRENT COLORECTAL CANCER REPORTS, 2013, 9 (03) : 261 - 269
  • [36] Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer
    Israeli, Eitan
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2022, 24 (07): : 481 - 481
  • [37] T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy
    An, Min Sung
    Yoo, Jong Han
    Kim, Kwang Hee
    Bae, Ki Beom
    Choi, Chang Soo
    Hwang, Jin Won
    Kim, Ji Hyun
    Kim, Bo Mi
    Kang, Mi Seon
    Oh, Min Kyung
    Hong, Kwan Hee
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2015, 13
  • [38] Stage II patients in the "MOSAIC" trial evaluating Oxaliplatin/5FU/LV as adjuvant treatment of colon cancer: a subpopulation analysis
    Hickish, Tamas
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Bonetti, Andrea
    Clingan, Philip
    Figer, Arie
    Andre, Thierry
    de Gramont, Aimery
    ANNALS OF ONCOLOGY, 2004, 15 : 76 - 76
  • [39] Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
    Tie, Jeanne
    Cohen, Joshua D.
    Lahouel, Kamel
    Lo, Serigne N.
    Wang, Yuxuan
    Kosmider, Suzanne
    Wong, Rachel
    Shapiro, Jeremy
    Lee, Margaret
    Harris, Sam
    Khattak, Adnan
    Burge, Matthew
    Harris, Marion
    Lynam, James
    Nott, Louise
    Day, Fiona
    Hayes, Theresa
    McLachlan, Sue-Anne
    Lee, Belinda
    Ptak, Janine
    Silliman, Natalie
    Dobbyn, Lisa
    Popoli, Maria
    Hruban, Ralph
    Lennon, Anne Marie
    Papadopoulos, Nicholas
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Tomasetti, Cristian
    Gibbs, Peter
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (24): : 2261 - 2272
  • [40] T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy
    Min Sung An
    Jong Han Yoo
    Kwang Hee Kim
    Ki Beom Bae
    Chang Soo Choi
    Jin Won Hwang
    Ji Hyun Kim
    Bo Mi Kim
    Mi Seon Kang
    Min Kyung Oh
    Kwan Hee Hong
    World Journal of Surgical Oncology, 13
12345